AbbVie Places $1.2 Billion Bet on Next-Generation “Non-Hallucinogenic” Psychedelic Drug Aug 25, 2025 Life Science
Revolutionizing Cancer Treatment With DNA Damage Response Inhibitor Technology – Rakovina Therapeutics | GCFF Sep 23, 2023 Others
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing Nov 11, 2021 Life Science
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team Nov 9, 2021 Life Science
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy Oct 18, 2021 Life Science
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor Oct 12, 2021 Life Science
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents Sep 16, 2021 Life Science
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies Jul 7, 2021 Life Science
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021 Life Science
